Pete Stavropoulos

Stock Analyst at Cantor Fitzgerald

(2.76)
# 2,000
Out of 5,044 analysts
52
Total ratings
32.65%
Success rate
2.74%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Pete Stavropoulos

Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $8.38
Upside: +114.80%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.55
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.36
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $53.94
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107$100
Current: $29.36
Upside: +240.60%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.61
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.44
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.74
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.96
Upside: -
Annexon
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.19
Upside: -
Reiterates: Overweight
Price Target: n/a
Current: $8.80
Upside: -
Initiates: Overweight
Price Target: n/a
Current: $33.82
Upside: -
Reiterates: Overweight
Price Target: $5
Current: $9.53
Upside: -47.53%
Reiterates: Overweight
Price Target: $13
Current: $2.26
Upside: +475.22%
Reiterates: Overweight
Price Target: $8
Current: $15.76
Upside: -49.24%